Navigation Links
Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM

TSX Exchange Symbol: RVX

CALGARY, Oct. 4 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that the Company is making an oral presentation of key scientific data of its lead clinical candidate, RVX-208, at the 16th International Symposium for Drugs Affecting Lipid Metabolism (DALM). The presentation titled, "A novel drug RVX-208 raises plasma apolipoprotein A-l and HDL cholesterol", will be presented by Dr. Norman Wong on October 4, 2007 at the Hilton Hotel in New York City.

"DALM is a premier international conference renowned for its content of state of the art therapeutics for the prevention of atherosclerosis and other cardiovascular diseases. We are pleased that Resverlogix will present its data detailing RVX-208, a small molecule drug which enhances the production of ApoA-l and HDL," stated Dr. Jan Johansson, Senior Vice President of Clinical Affairs of Resverlogix. Dr. Johansson added, "The scientific community recognizes the importance of a small molecule in the form of an oral tablet that significantly increases ApoA-I production, thereby enhancing the function of HDL. These beneficial effects of RVX-208 will potentially reduce the risk of atherosclerosis and cardiovascular disease."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Note to editors: Ken Lebioda, Senior Vice-President, will be attending the conference and can meet in person with interested media.

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. UW-Madisons Beebe wins scientific award
5. Researchers say scientific reporting needs more perspective, less hype
6. Wisconsin stands at the center of scientific efforts to avert flu epidemics
7. Growth prompts new location for scientific instrument manufacturer
8. UW stem cell guru outlines scientific and political future
9. Wisconsin biotech sector featured in scientific magazine
10. Scientific Protein Laboratories Acquired by New York firm
11. GenTel Appoints Burke to its Scientific Advisory Board
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... Creation Technologies would like to extend ... 2015 Technology Fast 500 list of the fastest growing companies in North America. ... medical device that speeds up orthodontic tooth movement by as much as 50 ...
(Date:11/24/2015)... CHARLOTTESVILLE, Va. , Nov. 24, 2015 /PRNewswire/ ... company focused on discovering drugs for metabolic disorders, ... Watkins to its Board of Directors (BOD). ... executive officer of Human Genome Sciences (HGS), and ... Industry Organization. Jim Powers , Chairman ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce ... stand-alone facility will be strictly dedicated to basic USP 61, USP 62 and USP ... chance to have complete chemistry and micro testing performed by one supplier. Management ...
(Date:11/23/2015)... THOUSAND OAKS, Calif., Nov. 23, 2015   Ceres, ... company, announced today financial results for the fiscal year ... its business. --> --> ... on commercializing forage and feed products with a better ... the company signed distribution agreements with several leading crop ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):